Monoclonal antibodies (MAbs) prepared against the yellow fever virus (YF) vaccine strain 17D (17D YF) envelope E protein were used to investigate Fc piece involvement in antibody-mediated protection against YF encephalitis in mice. 17D YF passaged either in Vero cells or in mouse brain (P-YF) to increase neurovirulence was used. To avoid uncertainty concerning antibody clearance and blood-brain barrier penetration, and to directly compare protective activity with neutralization in vitro, pre-formed antibody-virus complexes were injected intracerebrally or assayed for plaque formation in parallel. F(ab')~ fragments of an IgG2a MAb that strongly neutralized both YF strains retained molar equivalent neutralizing activity in vitro, but did not protect. However, further incubation of such F(ab')2-virus antibody complexes with rabbit IgG, but not F(ab')2 anti-mouse IgG resulted in protection. To unambiguously test for Fc piece involvement in this model we derived an IgG2a isotype switch variant from a protective IgG1 MAb-secreting hybridoma and prepared F(ab')2 fragments of the derivative. Intact and fragmented antibodies exhibited weak neutralizing activity. The variant antibody failed to protect against P-YF, but against considerably less neurovirulent 17D YF its protective capacity was 10-fold higher than that of its IgG1 parent. F(ab')2 fragments of the variant did not protect. Together, these results provide strong evidence of an in vivo protective function for the anti-virion antibody Fc piece and indicate that in vitro neutralizing activity as a predictor of antibody protective capacity is dependent on Fc piece integrity and isotype.
Antibody is an important element of the protective immune response against flavivirus infection of the central nervous system (CNS) (Monath, 1986) , but characteristics predictive of its in vivo activity are poorly defined. Viral infection in mice preferentially stimulates production of IgG2a antibody and dramatically shifts the ratio of IgG1/IgG2a (Coutelier et al., 1987) . IgG2a antibodies fix complement efficiently and direct immune cellular activity, Fc piece functions generally not mediated by IgG1 antibody. Thus IgG2a anti-virion antibodies that neutralize in vitro seem intuitively desirable but protection experiments in mice involving passively transferred monoclonal anti-flavivirus antibodies have been inconclusive in this respect. In the present work, we sought to directly compare the infectivity of pre-formed antibody-yellow fever virus (YF) complexes for both cultured cells and mice after intracerebral inoculation. The latter, which avoids uncertainty concerning antibody clearance and penetration of the blood-brain barrier, * Author for correspondence. Fax + 1 716 544 1504. inherent to previous protection studies, had been the traditional test of anti-flavivirus serum neutralizing activity (Theiler & Downs, 1973) . Experiments were designed to examine the relevance of in vitro neutralizing activity to protection in vivo and to test the importance of the Fc piece to anti-virion antibody protective capacity. An IgG2a (2El0) and an IgG1 (3A3) monoclonal antibody (MAb), prepared against the YF vaccine strain 17D (Schlesinger et al., 1983) , were chosen for study. These antibodies are directed at proximate virion envelope (E) protein epitopes (Schlesinger et al., 1984) , and exhibit markedly different in vitro neutralizing and protective capacities (described below). The neutralizing activity of MAb 2E 10 depends on recognition of a major antigenic determinant that maps to a single amino acid in an unconserved region of the E protein (Lobigs et al., 1987) .
Challenge viruses of differing neurovirulence were used to further characterize antibody activity. These were Vero cell-passaged 17D YF (100 p.f.u./LDs0 ) and a YF strain (P-YF; 10 p.f.u./LD~0 ), derived by serial brain passage of 17D YF in suckling mice (courtesy of Dr James Porterfield (Green Valleys, Goodleigh Barnstable, Devon, UK). The latter spreads throughout the CNS with striking rapidity after intracerebral inoculation, reaches CNS tissue titres up to 10000-fold higher than Vero cell passaged 17D YF, and kills mice significantly more quickly than the latter at identical LDs0 challenge inocula (J. J. Schlesinger, unpublished). F(ab')2 fragments of strongly neutralizing MAb 2El0 were prepared by pepsin digestion of affinity purified antibody using the method of Parham (1983) . Separation of F(ab')2 from Fc pieces and residual intact IgG was achieved by adsorption to Staphylococcus Protein A and was confirmed by SDS-PAGE and silver staining. Protein concentrations were determined by absorbance at 280nm and by densitometry after agarose gel electrophoresis. End-point titres were equivalent (ca. 1 / 10 000) when equimolar amounts of chromatographically purified intact immunoglobulin or F(ab')2 fragment were compared in a conventional plaque reduction assay employing Vero cells.
Four-week-old female outbred CD1 mice, used in all protection experiments, were observed for 21 days after intracerebral challenge. Graded equimolar amounts of intact or fragmented MAb 2El0 were incubated with 1 x 106 p.f.u, of P-YF in 600 pl MEM for 2 h at 37 °C before intracerebral injection of 8000-10000 p.f.u. (ca. 1000 LDs0 ) or simultaneous plaque assay of the inoculum in Vero cells. The in vitro neutralizing activity, here measured as the fraction of non-neutralized virus (nnf) remaining after antibody-virus contact, and protective capacity of the antibody preparations are summarized in Table 1 (a). At the highest antibody concentrations, both forms of MAb 2E 10 exhibited strong in vitro neutralizing activity which diminished in parallel on dilution. However, whereas the intact antibody was protective at relatively low concentrations only partial, statistically insignificant (P < 0.083) protection by the F(ab')~ fragment was found at the highest concentration used, possibly the effect of undetected contaminating intact antibody. Failure of the F(ab')2 moiety to protect against lethal infection despite strong in vitro neutralizing activity could be overcome by further incubation of the infectious immune complexes with anti-mouse IgG antibody. To accomplish this, immune complexes were prepared as follows: 10000p.f.u. P-YF and 8 lag (6.7x 10 5mM) F(ab')~ of neutralizing MAb 2E 10 or of control myeloma protein PC5 per mouse challenge dose were incubated at 37 °C for 1"5 h followed by addition of an equivalent amount of rabbit IgG or F(ab')2 anti-mouse IgG, or nonimmune rabbit IgG. After further incubation for 30 rain at 37 °C, mice were challenged by intracerebral injection of the respective virus-antibody mixture. Only mice challenged with F(ab')2-virus complexes further treated with intact immune rabbit IgG survived (Table 2 ).
These results suggested that the Fc moiety is required for optimal protection by an anti-E antibody, but provided no information about the possible importance of antibody isotype. In preliminary tests we found that IgG1 MAb 3A3 neutralized both YF strains relatively weakly under these experimental conditions and conferred protection only at the highest antibody concentration (Table I b , c) . To test the possibility that the IgG2a form of this antibody might exhibit enhanced protection against YF challenge, we used the sib selection method (Spira et al., 1984) to derive a stable IgG2a isotype switch variant, 3A3v. Briefly, 3A3 hybridoma cells, freshly recloned by limiting dilution, were distributed among multiple 96-well microtitre plates and screened by ELISA for the emergence of IgG2a-secreting cells using goat anti-mouse heavy chain isotype specific capture antibody (Southern Biotechnology Associates) and an alkaline phosphatase-labelled goat anti-mouse IgG probe. Repeated selection cycles resulted in enrichment of the IgG2a-secreting variant hybridoma, and a stable cell line, 3A3v, was established by cloning multiple times by limiting dilution. Specificity for YF was established by immunofluorescence assay using 17D YF-infected Vero cells. MAb 3A3v exhibited weaker neutralizing activity (residual nnf 0"50 %) than its parent at the highest concentration used and failed to protect against lethal challenge with P-YF (Table 1 b) . Residual nnf values were essentially identical when these antibodies were compared against the less neurovirulent 17D YF but against this virus the protective capacity of the IgG2a variant antibody was 10-fold higher than that of its IgG1 parent. F(ab')2 fragments of MAb 3A3v and antibody-virus complexes for intracerebral challenge were prepared and evaluated (Table 1 c). Neutralizing activity of MAb 3A3v F(ab')2 was 100-fold weaker than that of the intact antibody (nnf 0.10% vs < 0.001%) and, concordant with results obtained with MAb 2El0, removal of the IgG2a Fc piece abrogated protection (Table 1 c) .
Taken together, these data indicate that in vitro neutralizing activity may be predictive of protective capacity but that this characteristic is dependent on Fc piece integrity and isotype. Our results obtained with F(ab')2 fragments of MAbs directed at different epitopes are in agreement with those of Mathews et al. (1985) and Baldridge & Buchmeier (1992) who showed that a neutralizing monoclonal F(ab')2 fragment (delivered intravenously) against Venezuelan equine encephalitis virus or lymphocytic choriomeningitis virus (LCMV), respectively, was not protective against viral challenge whereas the intact antibody was. Anti-LCMV IgG2a MAbs were uniformly protective, but IgG1 MAbs which mapped to the same epitopes were not, even if neutralizing. The notion of Fc piece importance to anti-virion antibody protective capacity is further strengthened by our finding of strongly diminished neurovirulence of F(ab')~-virus complexes after binding to IgG. Evidence that change in the heavy chain alone can significantly influence the protective capacity of antibodies directed to the same virion protein epitope was provided by results with IgG1 MAb 3A3 and its IgG2a derivative (3A3v) against homologous 17D YF. Failure of the IgG2a variant to protect against the more neurovirulent heterologous P-YF strain may be explained by reduced binding affinity reflected in weaker neutralizing activity against this virus. That pertubation of the MAb 3A3 Fc piece affects antibody binding is also indicated by the reduced neutralizing activity of the 3A3v F(ab')2 fragment. Earlier observations that antibody-mediated protection against YF encephalitis in mice depended on the degree of neurovirulence of the challenge YF strain (Gould et al., 1986) are also relevant to our results.
These experiments, involving only two antibodies, have not defined a specific protective effector function directed by the Fc piece, but together with a similar finding of enhanced protection by IgG2a antibodies against the YF non-structural protein NS1 (Schlesinger et al., 1993) offer strong evidence that change in the heavy chain alone can significantly influence the capacity of antibodies to defend against flavivirus infection of the CNS. More than likely a number of mechanisms operate that vary with the specific target viral antigen and its site of antibody recognition within the CNS. Among these are Fc piece-directed complement fixation and activation of Fc receptor-bearing monocytic effector cells, and possibly altered antigen binding affinity that may result from structural changes in the Fc region. However, in view of recent evidence that antibody can interfere with virus replication intraneuronally, at a transcriptional or translational level (Levine et al., 1991) , the possibility of an entirely novel Fc piece-associated function cannot be dismissed.
